Melanoma News and Research

Latest Melanoma News and Research

Researchers identify tumor suppressor genes that drive subset of melanomas

Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that appeared today in Nature Genetics, a Weizmann Institute of Science team has now revealed one of the drivers of a particularly deadly subset of melanomas - one that is still seeing a rise in new cases. This gene is a newly identified member of a group of genes called tumor suppressor genes.

3 Nov 2015

UNM CCC biostatisticians help scientists conduct research on cancer

In contrast to most people, Ji-Hyun Lee, DrPH, doesn't find statistics difficult or boring. For her, statistics is fulfilling because it's how she helps people fight cancer. "People think biostatistics is purely numbers," Lee says, "but my work helps to improve patients' care." She recalls a visit to a hospital patient as a young statistician working for a cystic fibrosis research team.

29 Oct 2015

New research shows that autophagy can operate in cell nucleus to guard against start of cancer

Autophagy, literally self-eating or the degradation of unwanted cellular bits and pieces by the cell itself, has been shown for the first time to also work in the cell nucleus. In addition, in this setting it plays a role in guarding against the start of cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Oct 2015

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. These results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic. This work is being presented Oct. 28 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.

29 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015

Imlygic approved for treatment of melanoma lesions in the skin and lymph nodes

The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes.

28 Oct 2015

Discovery may open new doors to understanding how melanoma grows and spreads

Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that recently appeared in Nature Genetics, a Weizmann Institute of Science team has now revealed one of the drivers of a particularly deadly subset of melanomas that is seeing a rise in new cases.

27 Oct 2015

New drug combination may be effective against malignant melanoma

A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination - pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway - was discovered through one of the largest screens of cancer drug combinations conducted to date.

27 Oct 2015

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

New joint initiative to explore clinical interpretation of molecular tests for cancers

A new conference helping doctors navigate one of the most important scientific questions faced by the cancer community could help improve survival rates for patients.

23 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

Patrolling monocytes may play anti-cancer role in the lung

One goal of immunotherapy is to rally a patient's often over-burdened immune cells to effectively attack a tumor. Among foot soldiers on the immune front line is a subpopulation of white blood cells called "patrolling monocytes," whose job is to cruise the bloodstream, cart off cellular debris, and block invasion of a less benign population of inflammatory cells.

23 Oct 2015

Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography technology, today announces data showing that use of its VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma at an earlier stage and reduces diagnostic biopsies by 36%.

22 Oct 2015

Sequenom enters into clinical collaboration with CU School of Medicine

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine.

19 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

New research raises hope for novel cancer immunotherapy

New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

16 Oct 2015

Melanoma News and Research

Latest Melanoma News and Research

Researchers identify tumor suppressor genes that drive subset of melanomas

UNM CCC biostatisticians help scientists conduct research on cancer

New research shows that autophagy can operate in cell nucleus to guard against start of cancer

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Imlygic approved for treatment of melanoma lesions in the skin and lymph nodes

Discovery may open new doors to understanding how melanoma grows and spreads

New drug combination may be effective against malignant melanoma

New approaches to treating lung cancer patients in New Mexico

New joint initiative to explore clinical interpretation of molecular tests for cancers

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Patrolling monocytes may play anti-cancer role in the lung

Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Sequenom enters into clinical collaboration with CU School of Medicine

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

New research raises hope for novel cancer immunotherapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in